Skip to main content
main-content

Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in oncology

Virtual Simulations

Treating patients with castration-sensitive prostate cancer

This activity is intended for US healthcare providers and was made possible by educational funding provided by Astellas Pharma.

Conference highlights

Browse highlights from the 2022 American Society of Clinical Oncology Annual Meeting, June 3–7.

The latest in HR+/HER2- early breast cancer from ASCO 2022

This activity is supported by an educational grant from Lilly.

New additions to the Adis Journal Club – June update

Browse June's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

Expert discussion & interview

Early-stage NSCLC management – surgery, targeted treatment and immunotherapy

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Digital treatment map for ALK- and ROS1-mutated NSCLC

This independent content was supported by an educational grant from Pfizer.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

IN FOCUS | Lung & thoracic cancers

06-06-2022 | ASCO 2022 | Conference coverage | News

Acetaminophen may blunt ICI response in people with cancer

French researchers have identified an association between detectable plasma levels of acetaminophen and poor outcomes in people receiving immune checkpoint inhibitors for advanced cancer.

  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

IN FOCUS | Breast cancer

06-06-2022 | ASCO 2022 | Conference coverage | News

DESTINY-Breast04 ‘practice changing’ for HER2-low metastatic breast cancer

Trastuzumab deruxtecan significantly improves the survival outcomes of previously treated patients with HER2-low metastatic breast cancer relative to standard chemotherapy, show DESTINY-Breast04 data.

  • » This activity is supported by an educational grant from Lilly.

IN FOCUS | Genitourinary cancers

22-06-2022 | Prostate cancer | News

Enzalutamide during active surveillance may delay prostate cancer progression

The ENACT trial has demonstrated a significantly reduced risk for progression with the use of enzalutamide in men with low- or intermediate-risk localized prostate cancer undergoing active surveillance.

  • » This activity is intended for US healthcare providers and was made possible by educational funding provided by Astellas Pharma.

IN FOCUS | COVID-19 & cancer

24-02-2022 | ASCO GU 2022 | Conference coverage | Video

Mapping the impact of COVID-19 on genitourinary cancers

Chris Labaki takes us through his study evaluating temporal changes in the screening, diagnosis, and surgical treatment of genitourinary malignancies during the first year of the COVID-19 pandemic.

Stay informed with Medicine Matters

Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox

Podcasts

Interviews with clinical experts on cancer patient care